Friday, August 21, 2026 In today's episode, Dr. Will Flanary (@drglaucomflecken) & Eva Johnson cover a historic drop in prescription drug prices. Prices fell 3.1% over the past year, the steepest annual decline since 1963, and the anchors unpack what is actually driving it from generics to GLP-1 competition to…
Friday, August 14, 2026 In today's episode, Adam Rose (@adjoro) & Dr. Alok Patel (@alokpatelmd) cover the FDA's landmark approval of Moderna's first mRNA flu vaccine for adults. They break down the phase-three trial showing the mRNA shot produced fewer confirmed influenza cases than standard vaccines, and what a complicated…
August 7, 2026 In today's episode, Dr. Will Flanary (@DrGlaucomflecken) & Eva Johnson cover the American Red Cross declaring its second-ever national blood crisis, with Type O blood critically low and hospitals postponing transfusions. They break down what's driving the shortage and debate whether blood donors deserve HOV-lane perks. Then:…
Friday, July 31, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Adam Rose (@adjoro) cover a Florida man's lawsuit against OpenAI after ChatGPT repeatedly dismissed his pulmonary embolism symptoms as "not something dangerous." The case raises urgent questions about AI medical liability just as a new JAMA analysis reveals…
Friday, July 24, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Eva Johnson cover CMS's sweeping 2027 physician fee schedule proposal, which would accelerate Medicare's shift from fee-for-service toward value-based, preventive care. They also unpack Kalshi's launch of clinical trial prediction markets; betting on FDA approvals is now a…
Friday, July 17, 2026 In today’s episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) and Adam Rose cover the EPCAT III trial, which found that aspirin alone was non-inferior to an initial course of rivaroxaban followed by aspirin for preventing major blood clots after elective hip or knee replacement in…
Friday, July 10, 2026 In today's episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) & Eva Johnson cover the retraction of the Advocate trial after FDA reviewers found the avacopan (Tavneos) dataset was unblinded, re-adjudicated, and altered before being relocked, throwing its approval for ANCA-associated vasculitis into doubt. They break…
In today's inaugural episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) & Dr. Alok Patel (@alokpatelmd) cover a sharp drop in ACA marketplace enrollment after enhanced tax credits expired, from 24.2 million enrollees in 2025 to roughly 19.2 million in 2026 (a loss of 5 million Americans' health coverage). India…
Struggling to stay on top of healthcare news because, well, you're too busy working in it? If only there were a way to catch up on things in less time than it takes to get prior auth approved. (Spoiler: There is.) Kick off your Fridays with Dr. Will Flanary (aka…